In vivo multiphoton imaging reveals gradual growth of newborn amyloid plaques over weeks
- First Online:
- Cite this article as:
- Burgold, S., Bittner, T., Dorostkar, M.M. et al. Acta Neuropathol (2011) 121: 327. doi:10.1007/s00401-010-0787-6
The kinetics of amyloid plaque formation and growth as one of the characteristic hallmarks of Alzheimer’s disease (AD) are fundamental issues in AD research. Especially the question how fast amyloid plaques grow to their final size after they are born remains controversial. By long-term two-photon in vivo imaging we monitored individual methoxy-X04-stained amyloid plaques over 6 weeks in 12 and 18 months old Tg2576 mice. We found that in 12 months old mice, newly appearing amyloid plaques were initially small in volume and subsequently grew over time. The growth rate of plaques was inversely proportional to their volume; thus amyloid plaques that were already present at the first imaging time point grew over time but slower compared to new plaques. Additionally, we analyzed 18 months old Tg2576 mice in which we neither found newly appearing plaques nor a significant growth of pre-existing plaques over 6 weeks of imaging. In conclusion, newly appearing amyloid plaques are initially small in size but grow over time until plaque growth can not be detected anymore in aged mice. These results suggest that drugs that target plaque formation should be most effective early in the disease, when plaques are growing.
KeywordsAlzheimer’s disease Amyloid plaque Aβ, plaque growth Tg2576 Two-photon In vivo Imaging
Amyloid plaques represent one of the major hallmarks of Alzheimer’s disease (AD) pathology. They are comprised of fibrillar aggregates of the amyloid-β-peptide which has been shown to have synaptotoxic effects [10, 17, 18, 23]. In AD patients as well as in animal models synapse loss is most prominent in close proximity to amyloid plaque deposits which indicates a link between amyloid plaques and synaptotoxicity [7, 14, 15, 19, 20, 21]. Therefore, elucidating the process of amyloid plaque formation and growth may reveal important targets for therapeutic interventions to stop the progression of synapse loss and consequently cognitive decline in AD.
In vitro studies of plaque formation established a model in which a seed of fibrillar Aβ is formed first and plaques grow subsequently around these seeds in a time- and concentration-dependent manner [4, 11]. These findings were corroborated by in vivo imaging studies of AD transgenic (APP/PS1) mice, which reported a change in size of a subset of plaques  or a gradual growth of almost all plaques, which was faster in smaller plaques and younger animals . These findings, however, are contrasted by different studies, which reported that Aβ plaques appeared rapidly in both APP/PS1 and Tg2576 transgenic mice  and that these were relatively stable over time in Tg2576 transgenic mice . The apparent discrepancies of the in vivo studies may be attributed to a different preparation of the cranial window (e.g., thinned skull vs. open skull preparations), the age of the mice, or different disease models (e.g., APP/PS1 or Tg2576). In order to reconcile these findings, we studied the appearance of Aβ plaques in detail. We followed plaque formation in 12 and 18 months old Tg2576 mice by measuring the volume, as well as area, over a period of 6 weeks. While we used an open skull preparation, we started our imaging protocol 3 weeks after surgery, so that possible artifacts from inflammatory reactions  were minimized.
Using this approach, we found that plaques appeared and increased in volume in 12 months old, but not in 18 months old mice. Nascent plaques were initially small in volume and grew over time. Pre-existing plaques, in contrast, had a larger volume and grew slower compared to newly formed ones. These findings demonstrate that Aβ plaques grow in a size-dependent manner in young (12 months) mice, while no growth was observed in older (18 months) mice.
Materials and methods
Heterozygous Tg2576  mice (B6;SJL-Tg(APPSWE)2576Kha from Taconic, Cologne, Germany) were crossed with heterozygous YFP-H  mice (B6.Cg-Tg(Thy1-YFPH)2Jrs/J) from The Jackson Laboratory, Bar Harbor, USA) expressing yellow fluorescent protein (YFP) in a subset of cortical neurons. YFP-labeled neurons served as a counterstaining to find the same imaging positions over and over again in subsequent time points. Mice were of both sexes and were group housed under pathogen-free conditions until surgery, after which they were singly housed. All procedures were performed in accordance with an animal protocol approved by the University of Munich and the Government of Upper Bavaria (55.2-1.54-2531-110-06).
A cranial window over the right cortical hemisphere was surgically implanted as previously described [1, 6, 8]. The mice were anesthetized with an intraperitoneal injection of ketamine/xylazine (0.13/0.01 mg/g body weight). Additionally, dexamethasone (0.02 ml at 4 mg/ml) was intraperitoneally administered immediately before surgery (Holtmaat et al. 2005). A circular piece of the skull (4 mm in diameter) over the right somatosensory cortex (centered over the parietal bone, approx. 5.5 mm caudal from the bregma and 5.5 mm lateral of the midline) was removed using a dental drill (Schick-Technikmaster C1; Pluradent; Offenbach, Germany). Immediately, a round coverslip (5 mm diameter) was glued to the skull using dental acrylic (Cyano-Veneer fast; Heinrich Schein Dental Depot, Munich, Germany) to close the craniotomy. A small metal bar, containing a hole for a screw, was glued next to the coverslip to allow repositioning of the mouse during subsequent imaging sessions. After surgery, mice received a subcutaneous analgesic dose of carprophen (Rimadyl; Pfizer, New York, USA) for 3 days (5 mg/kg). Imaging began following a 21 day rest period after surgery.
Long-term two-photon in vivo imaging
Long-term two-photon imaging was performed as previously described [1, 6]. Less than 50 mW laser power was delivered to the tissue to avoid laser-induced phototoxicity. For amyloid plaque staining, methoxy-X04  was intraperitoneally injected 24 h before every imaging session. Initially, we administered doses of 2.4 mg/kg. However, in an attempt to reduce methoxy-X04 usage, we changed the dosing regimen to an initial loading dose of 2.0 mg/kg before the first imaging session and subsequent weekly maintenance doses of 0.4 mg/kg, which did not affect the signal-to-noise ratio (data not shown). Furthermore, we found no significant difference in plaque growth between these two dosing regimens (Supplementary Fig. S1a), therefore we pooled the data for all further analyses. To determine whether repeated administration of methoxy-X04 increased the apparent volume of plaques by increasing the brightness, we correlated plaque volumes with the mean intensity of the fluorescence values of all voxels in a plaque (Supplementary Fig. S1b). The correlation between plaque volume and intensity was weak (R2 = 0.25) compared to data obtained by imaging fluorescent beads with varying laser intensities to simulate increasing brightness (R2 = 0.71; data not shown). Considering that no plaque growth was observed in older animals despite the same dosing scheme and that comparably little plaque growth was observed with daily administration of methoxy-X04 (Supplementary Fig. S2), changes in plaque volumes cannot be attributed to increased brightness due to methoxy-X04 accumulation.
YFP and methoxy-X04 were excited by a Ti:Sa laser (MaiTai, Spectra-Physics, Darmstadt, Germany) at 880 and 750 nm and the emission was collected from 527 to 582 nm and 460 to 500 nm, respectively (LSM 5MP, Zeiss, Jena, Germany). A Zeiss 20× water-immersion objective (1.0 NA) was used to acquire image stacks of 425 × 425 × 300 μm3 with 3 μm z-resolution and 1,024 × 1,024 pixels per image frame (0.41 μm/pixel). In subsequent imaging sessions, previously imaged volumes were identified by eye, based on the positions of blood vessels, neuronal cell bodies and processes, as well as plaques. This allowed the precise alignment of the same imaging volume over a period of 6 weeks. The laser intensity was adjusted to keep the emitted YFP fluorescence stable.
Image processing and data analysis
The 3D images were deconvolved (AutoDeblur, Version x2.0.1, Media Cybernetics, Bethesda, USA) and contrast-normalized (i.e., based on the average and standard deviation of intensities of 3D stacks; Imaris 6.2.1, Bitplane, Zurich, Switzerland). For 3D analysis, we used surface rendering by Imaris software which also calculated the volume of individual plaques over time period. The 2D analysis was performed in maximum intensity projections applying a threshold of mean intensity + twice standard deviation of a representative background region. The volume growth of individual plaques was quantified as the slope of a linear fit of the volumes measured at each time point. We used repeated measures ANOVA and Student’s t-test to test significance. All data are presented as mean ± SD, and 95% confidence intervals (95% CI) are given where appropriate.
We monitored the appearance and growth of Aβ plaques in Tg2576 mice by in vivo two-photon microscopy of animals pretreated with methoxy-X04, which stains Aβ plaques. As a model, we used Tg2576 mice, which overexpress a human APP transgene containing the Swedish FAD mutation (K670N/M671L), and display the slowest amyloid pathology  of all the models analyzed by Meyer-Luehmann et al. . We reasoned that if we were able to detect amyloid plaque growth in this model, then it should also be detectable in other mouse models with a faster amyloid pathology.
In summary, we showed that in the early stages of amyloid pathology in Tg2576 mice, newborn plaques are initially small in size and grow over time. These findings are in contrast to the previous study by Meyer-Luehmann et al.  which found that plaques appeared very rapidly (within 24 h) and did not change significantly in size thereafter. One possible reason for the differing results might be the fact that we primarily quantified volume, rather than area. However, even when we quantified plaque size as an area, that area steadily increased over 6 weeks (Figs. 3d, 4d). Thus, quantification of the plaques in three dimensions does not account for the observed difference. Another possibility is that open-skull surgery induces local inflammation and gliosis in the first weeks after surgery , which may affect plaque growth . Therefore, in contrast to Meyer-Luehmann et al. , we waited for 3 weeks before imaging, so that possible inflammatory responses could abate. Yet even when we started daily imaging immediately after cranial window surgery, we were able to measure plaque growth. Initial plaque volumes were 92.1 ± 64.5 μm3 (95% CI, 60.0–124 μm3; n = 18). However, a significant increase in plaque volume was only detected if we monitored plaque sizes for more than 16 days (Supplementary Fig. S2). Thus, delayed imaging 3 weeks after surgery does not account for the observed differences, either. We identified, however, two factors which determined if plaque growth can be observed in Tg2576 mice; first, and most importantly, we found that plaque growth can only be detected after a sufficiently long observation period. We monitored plaques for six consecutive weeks and detected that a statistically significant change in plaque volume of newborn plaques was achieved not earlier than 2 weeks after their first appearance (Fig. 3c), whereas a statistically significant change in plaque volume of pre-existing plaques was achieved not earlier than 4 weeks after the initial measurement (Fig. 4c). Second, we also found that the age of the observed animals plays an important role; we detected plaque growth in 12 months old mice, whereas 18 months old mice showed no significant overall growth of plaques (Figs. 5c, 6), which was shown before by Christie et al. . Glial interaction with amyloid deposits has previously been suggested as a possible explanation for this observation in old mice . However, we would further like to propose the possibility that the high number of existing amyloid plaques at this age and therefore the large total surface area where newly formed Aβ fibrils can attach to existing plaques could lead to a decelerated growth of each individual plaque up to a degree that it is not detectable by two-photon in vivo imaging anymore. It is furthermore interesting to note that plaque size varied widely in 18 months old animals (Fig. 2); yet we observed no newborn plaques at that age (Fig. 6). Individual plaques, however, seemed both to shrink and grow between measurements (Fig. 5). While this suggests the exciting possibility that plaques might be in a dynamic equilibrium, increasing measurement errors with increasing plaque size (note the heteroscedasticity in Figs. 3c, 4c) preclude us from making a firm conclusion. Thus, our data show that both the appropriate age and an appropriate observation period are required in order to detect plaque growth. Furthermore, our findings corroborate results which showed plaque growth in different double-transgenic AD mouse models [2, 24].
In conclusion, we show that amyloid plaques do grow in 12 months old Tg2576 mice when amyloid pathology is in the early stages . Newborn amyloid plaques are initially small in size and grow over the following weeks. After the initial growth period, plaques continue to grow, albeit more slowly, until plaque growth is not detectable anymore in aged mice. These findings have important implications for AD diagnosis and therapy. A recent study , for instance, showed that in patients with mild cognitive impairment (MCI), amyloid plaque load, as measured by 11C-Pittsburgh compound B (PIB) retention in positron emission tomography, increased over 5 years, while the regional cerebral metabolic rate of glucose decreased. However, cognitive function remained stable in these patients. Patients with AD, in contrast, had higher PIB retention than patients with MCI, which did not increase further over the observation period, and showed a decline in the regional cerebral metabolic rate of glucose as well as in cognitive function. In combination with our results, these data suggest that plaque formation occurs early in the course of the disease, but before a loss of cognitive function becomes apparent. Therefore, drugs that target plaque formation should be most effective early in the disease, when plaques are growing. These results also suggest that a different mechanism may be responsible for the cognitive decline in patients with manifest AD. Thus, an effort has to be made to find the mechanism of cognitive decline in the late disease stages in order to tailor effective therapeutic strategies.
This work was supported by grants from the Deutsche Forschungsgemeinschaft (SFB 596, A13), the German Federal Ministry of Education and Research (Bundesministerium für Bildung und Forschung, 01GZ0713, 13N9268), the German Federal Ministry of Economics and Technology (Bundesministerium für Wirtschaft und Technologie, 16IN0675) and the European Union (Neuro.GSK3, FP-7-223276). Furthermore, the authors would like to thank Sonja Steinbach for her excellent technical assistance and Patrizia Bonert for her invaluable assistance in animal care.
This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.